Trial Profile
Phase 1 safety trial of bortezomib-based graft-versus-host disease prophylaxis in allogeneic hematopoietic stem cell transplantation from an HLA-mismatched unrelated donor in the Japan marrow donor program (JMDP)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Apr 2020
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Methotrexate; Tacrolimus
- Indications Graft-versus-host disease
- Focus Adverse reactions
- 31 Mar 2019 Status changed from active, no longer recruiting to completed.
- 05 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 12 Nov 2012 Actual initiation date changed from May 2012 to 16 Oct 2012 as reported by University Hospital Medical Information Network - Japan record.